Clinical Trial Update: 24 Months Follow-up, Two Arm Study to Compare the Cardiovascular Profile in a Regimen With Everolimus + Mycophenolic Acid (MPA) Versus (vs.) a Regimen of CNI+MPA in Maintenance Renal Transplant Recipients [Phase 4]

View source ↗

Summary

This Phase 4 trial update reports 24-month follow-up comparing cardiovascular outcomes between an everolimus plus mycophenolic acid regimen and a calcineurin in…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Transplantation

Drugs mentioned

• Everolimus (everolimus)
• Mycophenolic acid (mycophenolic acid)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Renal Transplant | Phase 4 | Status: COMPLETED | Results posted: 2015-04-30